You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company has rehired a core team of employees and is working on closing a "significant round of funding" from undisclosed potential investors or partners.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
In a Twitter message dated Dec. 4, the company said it is suspending its US operations for the time being "due to an unexpected adverse financing situation."
Veritas' offerings include the myGenome Standard whole-genome sequencing service, as well as the myGenome Premium and myGenome Diagnostic services.
In an effort to lift patient access barriers, the company is launching a model whereby consumers will be able to initiate test orders online.
The genetic testing community is having a tough time deciphering FDA's intentions based on its authorization of 23andMe’s PGx test and a recent safety alert.
Some partners are implementing their solutions on the Azure cloud while others will accept output from Microsoft's genomics pipeline as input into their solutions.
The startup plans to use blockchain to enable genomic data sharing and will partner with Veritas to gain access to its open-source software platform.
Through their partnership, Genomenon and Veritas Genetics hope to develop a new literature prioritization engine to bring down the cost of WGS interpretation.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.